Kinetic characterization of human mRNA guanine-N7 methyltransferase.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
24 Feb 2024
24 Feb 2024
Historique:
received:
01
01
2024
accepted:
21
02
2024
medline:
25
2
2024
pubmed:
25
2
2024
entrez:
24
2
2024
Statut:
epublish
Résumé
The 5'-mRNA-cap formation is a conserved process in protection of mRNA in eukaryotic cells, resulting in mRNA stability and efficient translation. In humans, two methyltransferases, RNA cap guanine-N7 methyltransferase (hRNMT) and cap-specific nucleoside-2'-O-methyltransferase 1 (hCMTr1) methylate the mRNA resulting in cap0 (N7mGpppN-RNA) and cap1 (N7mGpppN2'-Om-RNA) formation, respectively. Coronaviruses mimic this process by capping their RNA to evade human immune systems. The coronaviral nonstructural proteins, nsp14 and nsp10-nsp16, catalyze the same reactions as hRNMT and hCMTr1, respectively. These two viral enzymes are important targets for development of inhibitor-based antiviral therapeutics. However, assessing the selectivity of such inhibitors against human corresponding proteins is crucial. Human RNMTs have been implicated in proliferation of cancer cells and are also potential targets for development of anticancer therapeutics. Here, we report the development and optimization of a radiometric assay for hRNMT, full kinetic characterization of its activity, and optimization of the assay for high-throughput screening with a Z-factor of 0.79. This enables selectivity determination for a large number of hits from various screening of coronaviral methyltransferases, and also screening hRNMT for discovery of inhibitors and chemical probes that potentially could be used to further investigate the roles RNMTs play in cancers.
Identifiants
pubmed: 38402266
doi: 10.1038/s41598-024-55184-5
pii: 10.1038/s41598-024-55184-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4509Subventions
Organisme : NIH HHS
ID : U19AI171110
Pays : United States
Informations de copyright
© 2024. The Author(s).
Références
Muthukrishnan, S., Moss, B., Cooper, J. A. & Maxwell, E. S. Influence of 5’-terminal cap structure on the initiation of translation of vaccinia virus mRNA. J. Biol. Chem. 253, 1710–1715 (1978).
doi: 10.1016/S0021-9258(17)34923-2
pubmed: 627567
Ramanathan, A., Robb, G. B. & Chan, S. H. mRNA capping: Biological functions and applications. Nucleic Acids Res. 44, 7511–7526. https://doi.org/10.1093/nar/gkw551 (2016).
doi: 10.1093/nar/gkw551
pubmed: 27317694
pmcid: 5027499
Furuichi, Y. & Shatkin, A. J. Viral and cellular mRNA capping: past and prospects. Adv. Virus. Res. 55, 135–184. https://doi.org/10.1016/s0065-3527(00)55003-9 (2000).
doi: 10.1016/s0065-3527(00)55003-9
pubmed: 11050942
pmcid: 7131690
Ghosh, A. & Lima, C. D. Enzymology of RNA cap synthesis. Wiley Interdiscip. Rev. RNA 1, 152–172. https://doi.org/10.1002/wrna.19 (2010).
doi: 10.1002/wrna.19
pubmed: 21956912
pmcid: 3962952
Byszewska, M., Smietanski, M., Purta, E. & Bujnicki, J. M. RNA methyltransferases involved in 5’ cap biosynthesis. RNA Biol. 11, 1597–1607. https://doi.org/10.1080/15476286.2015.1004955 (2014).
doi: 10.1080/15476286.2015.1004955
pubmed: 25626080
Pillutla, R. C., Shimamoto, A., Furuichi, Y. & Shatkin, A. J. Human mRNA capping enzyme (RNGTT) and cap methyltransferase (RNMT) map to 6q16 and 18p11.22-p11.23, respectively. Genomics 54, 351–353. https://doi.org/10.1006/geno.1998.5604 (1998).
doi: 10.1006/geno.1998.5604
pubmed: 9828141
Tsukamoto, T., Shibagaki, Y., Niikura, Y. & Mizumoto, K. Cloning and characterization of three human cDNAs encoding mRNA (guanine-7-)-methyltransferase, an mRNA cap methylase. Biochem. Biophys. Res. Commun. 251, 27–34. https://doi.org/10.1006/bbrc.1998.9402 (1998).
doi: 10.1006/bbrc.1998.9402
pubmed: 9790902
Saha, N., Schwer, B. & Shuman, S. Characterization of human, Schizosaccharomyces pombe, and Candida albicans mRNA cap methyltransferases and complete replacement of the yeast capping apparatus by mammalian enzymes. J. Biol. Chem. 274, 16553–16562. https://doi.org/10.1074/jbc.274.23.16553 (1999).
doi: 10.1074/jbc.274.23.16553
pubmed: 10347220
Shafer, B., Chu, C. & Shatkin, A. J. Human mRNA cap methyltransferase: Alternative nuclear localization signal motifs ensure nuclear localization required for viability. Mol. Cell Biol. 25, 2644–2649. https://doi.org/10.1128/MCB.25.7.2644-2649.2005 (2005).
doi: 10.1128/MCB.25.7.2644-2649.2005
pubmed: 15767670
pmcid: 1061643
Gonatopoulos-Pournatzis, T., Dunn, S., Bounds, R. & Cowling, V. H. RAM/Fam103a1 is required for mRNA cap methylation. Mol. Cell 44, 585–596. https://doi.org/10.1016/j.molcel.2011.08.041 (2011).
doi: 10.1016/j.molcel.2011.08.041
pubmed: 22099306
pmcid: 3235549
Osborne, M. J. et al. Identification and characterization of the interaction between the methyl-7-guanosine cap maturation enzyme RNMT and the cap-binding protein eIF4E. J. Mol. Biol. 434, 167451. https://doi.org/10.1016/j.jmb.2022.167451 (2022).
doi: 10.1016/j.jmb.2022.167451
pubmed: 35026230
pmcid: 9288840
Blagden, S. P. & Willis, A. E. The biological and therapeutic relevance of mRNA translation in cancer. Nat. Rev. Clin. Oncol. 8, 280–291. https://doi.org/10.1038/nrclinonc.2011.16 (2011).
doi: 10.1038/nrclinonc.2011.16
pubmed: 21364523
Dunn, S., Lombardi, O., Lukoszek, R. & Cowling, V. H. Oncogenic PIK3CA mutations increase dependency on the mRNA cap methyltransferase RNMT, in breast cancer cells. Open Biol. 9, 190052. https://doi.org/10.1098/rsob.190052 (2019).
doi: 10.1098/rsob.190052
pubmed: 30991934
pmcid: 6501644
Chen, H. et al. Preferential expression of B7–H6 in glioma stem-like cells enhances tumor cell proliferation via the c-Myc/RNMT axis. J. Immunol. Res. 2020, 2328675. https://doi.org/10.1155/2020/2328675 (2020).
doi: 10.1155/2020/2328675
pubmed: 32322592
pmcid: 7165331
Lu, Y. et al. Porcine epidemic diarrhea virus deficient in RNA cap guanine-N-7 methylation is attenuated and induces higher type I and III interferon responses. J. Virol. 94, E00447. https://doi.org/10.1128/JVI.00447-20 (2020).
doi: 10.1128/JVI.00447-20
pubmed: 32461321
pmcid: 7394890
Katinka, M. D. et al. Genome sequence and gene compaction of the eukaryote parasite Encephalitozoon cuniculi. Nature 414, 450–453. https://doi.org/10.1038/35106579 (2001).
doi: 10.1038/35106579
pubmed: 11719806
Fabrega, C., Hausmann, S., Shen, V., Shuman, S. & Lima, C. D. Structure and mechanism of mRNA cap (guanine-N7) methyltransferase. Mol. Cell 13, 77–89. https://doi.org/10.1016/s1097-2765(03)00522-7 (2004).
doi: 10.1016/s1097-2765(03)00522-7
pubmed: 14731396
Zheng, S. et al. Mutational analysis of Encephalitozoon cuniculi mRNA cap (guanine-N7) methyltransferase, structure of the enzyme bound to sinefungin, and evidence that cap methyltransferase is the target of sinefungin’s antifungal activity. J. Biol. Chem. 281, 35904–35913. https://doi.org/10.1074/jbc.M607292200 (2006).
doi: 10.1074/jbc.M607292200
pubmed: 16971388
Encinar, J. A. & Menendez, J. A. Potential drugs targeting early innate immune evasion of SARS-Coronavirus 2 via 2’-O-methylation of viral RNA. Viruses 12, 525. https://doi.org/10.3390/v12050525 (2020).
doi: 10.3390/v12050525
pubmed: 32397643
pmcid: 7291090
Devkota, K. et al. Probing the SAM binding site of SARS-CoV-2 Nsp14 in vitro using SAM competitive inhibitors guides developing selective bisubstrate inhibitors. SLAS Discov. 26, 1200–1211. https://doi.org/10.1177/24725552211026261 (2021).
doi: 10.1177/24725552211026261
pubmed: 34192965
Khalili Yazdi, A. et al. A high-throughput radioactivity-based assay for screening SARS-CoV-2 nsp10-nsp16 complex. SLAS Discov. 26, 757–765. https://doi.org/10.1177/24725552211008863 (2021).
doi: 10.1177/24725552211008863
pubmed: 33874769
Perveen, S. et al. A high-throughput RNA displacement assay for screening SARS-CoV-2 nsp10-nsp16 complex toward developing therapeutics for COVID-19. SLAS Discov. 26, 620–627. https://doi.org/10.1177/2472555220985040 (2021).
doi: 10.1177/2472555220985040
pubmed: 33423577
Li, F. et al. SS148 and WZ16 inhibit the activities of nsp10-nsp16 complexes from all seven human pathogenic coronaviruses. Biochim. Biophys. Acta Gen. Subj. 1867, 130319. https://doi.org/10.1016/j.bbagen.2023.130319 (2023).
doi: 10.1016/j.bbagen.2023.130319
pubmed: 36764586
pmcid: 9908617
Issur, M., Picard-Jean, F. & Bisaillon, M. The RNA capping machinery as an anti-infective target. Wiley Interdiscip. Rev. RNA 2, 184–192. https://doi.org/10.1002/wrna.43 (2011).
doi: 10.1002/wrna.43
pubmed: 21957005
Zhang, J. H., Chung, T. D. & Oldenburg, K. R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen 4, 67–73. https://doi.org/10.1177/108705719900400206 (1999).
doi: 10.1177/108705719900400206
pubmed: 10838414
Yeon, S. Y. et al. Frameshift mutations in repeat sequences of ANK3, HACD4, TCP10L, TP53BP1, MFN1, LCMT2, RNMT, TRMT6, METTL8 and METTL16 genes in colon cancers. Pathol. Oncol. Res. 24, 617–622. https://doi.org/10.1007/s12253-017-0287-2 (2018).
doi: 10.1007/s12253-017-0287-2
pubmed: 28803425
Bunnage, M. E., Chekler, E. L. & Jones, L. H. Target validation using chemical probes. Nat. Chem. Biol. 9, 195–199. https://doi.org/10.1038/nchembio.1197 (2013).
doi: 10.1038/nchembio.1197
pubmed: 23508172
Singh, I. et al. Structure-based discovery of inhibitors of the SARS-CoV-2 Nsp14 N7-methyltransferase. J. Med. Chem. 66, 7785–7803. https://doi.org/10.1021/acs.jmedchem.2c02120 (2023).
doi: 10.1021/acs.jmedchem.2c02120
pubmed: 37294077
Otava, T. et al. The structure-based design of SARS-CoV-2 nsp14 methyltransferase ligands yields nanomolar inhibitors. ACS Infect. Dis. 7, 2214–2220. https://doi.org/10.1021/acsinfecdis.1c00131 (2021).
doi: 10.1021/acsinfecdis.1c00131
pubmed: 34152728
Aregger, M. & Cowling, V. H. Human cap methyltransferase (RNMT) N-terminal non-catalytic domain mediates recruitment to transcription initiation sites. Biochem. J. 455, 67–73. https://doi.org/10.1042/BJ20130378 (2013).
doi: 10.1042/BJ20130378
pubmed: 23863084